Fischer Medical Ventures Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Fischer Medical Ventures Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than almost all Healthcare companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹-548 of operating cash. Lower than almost all Healthcare companies in India.
- Cash Locked Ratio: For every ₹100 of sales, ₹63 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹75 tied up three years earlier. More money tied up than 98% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹-548Over the last 3 years, every ₹100 of reported profit came with ₹-548 of operating cash.
Lower than almost all Healthcare companies in India.
Self-Funding Ratio
-25.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than almost all Healthcare companies in India.
Cash Locked Ratio
₹63For every ₹100 of sales, ₹63 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹75 tied up three years earlier.
More money tied up than 98% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹10Sales grew 171,808% in 3 years; of every extra ₹100 of sales, ₹10 became extra profit.
Lower than 66% of Healthcare companies in India.
Asset Productivity Ratio
+171808% / +189719%In 3 years sales changed by +171808% while total assets changed by +189719%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-1.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 96% of Healthcare companies in India.
Cash Cushion Ratio
−5%Debt, after subtracting cash, equals 5% of its market value (net debt).
Lower than 65% of Healthcare companies in India.
Tangible Assets Ratio
99%Of every ₹100 the company owns, ₹99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 63% of Healthcare companies in India.
Tangible Net Worth Ratio
99%Of every ₹100 of net worth, ₹99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 63% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Fischer Medical Ventures Limited owes ₹0.43 for every ₹1 it owns. Net profit rose 2074% in the year to Mar 2026.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
10.6Investors pay ₹10.6 for every ₹1 of Fischer Medical Ventures Limited's yearly profit, lower than 96% of Healthcare companies in India.
P/B ratio
4.52The share price is 4.52 times Fischer Medical Ventures Limited's book value per share, lower than 52% of Healthcare companies in India.
Market cap
₹1,738 CrThe total market value of all of Fischer Medical Ventures Limited's shares at today's price (share price × number of shares), smaller than 70% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹384 CrWhat Fischer Medical Ventures Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹5.50Net worth divided by the number of shares. The share price of ₹24.88 is 4.5 times this, which is the P/B above.
Return on equity (ROE)
39.3%Fischer Medical Ventures Limited earned 39.3% on its shareholders' money over the last year, higher than 95% of Healthcare companies in India.
Owes vs Owns
0.43×Fischer Medical Ventures Limited owes ₹0.43 for every ₹1 it owns (low), higher than 66% of Healthcare companies in India.
Dividend yield
0.16%Fischer Medical Ventures Limited pays 0.16% of its share price as dividends a year, lower than 75% of dividend-paying Healthcare companies in India.
Revenue growth
+179%Revenue rose 179% in the year to Mar 2026, and grew 1098% a year on average over 3 years.
Profit growth
+2074%Net profit rose 2074% in the year to Mar 2026.
Profit margin
10.4%Fischer Medical Ventures Limited keeps ₹10 of every ₹100 of revenue as net profit.
Cash quality
-3.1×Cash from Fischer Medical Ventures Limited's business was -3.1× its reported profit in the year to Mar 2026 — the business used cash even though it reported a profit.
Interest cover
9.6×Fischer Medical Ventures Limited's operating profit covered its interest costs 9.6 times in the year to Mar 2026.
Cash vs debt
Net debtFischer Medical Ventures Limited had ₹82 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Fischer Medical Ventures Limited's P/E ratio?
Investors pay ₹10.6 for every ₹1 of Fischer Medical Ventures Limited's yearly profit, lower than 96% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Fischer Medical Ventures Limited: ₹1,738 Cr ÷ ₹384 Cr (31 Mar 2026) = 4.5.
What is Fischer Medical Ventures Limited's return on equity?
Fischer Medical Ventures Limited earned 39.3% on its shareholders' money over the last year, higher than 95% of Healthcare companies in India.
How much does Fischer Medical Ventures Limited owe compared with what it owns?
Fischer Medical Ventures Limited owes ₹0.43 for every ₹1 it owns (low), higher than 66% of Healthcare companies in India.
Does Fischer Medical Ventures Limited pay a dividend?
Yes. Fischer Medical Ventures Limited pays 0.16% of its share price as dividends a year, lower than 75% of dividend-paying Healthcare companies in India.
Is Fischer Medical Ventures Limited's revenue growing?
Revenue rose 179% in the year to Mar 2026, and grew 1098% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.